Patents by Inventor Douglas Lauffenburger

Douglas Lauffenburger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11408885
    Abstract: Proteases regulate a wide range of normal cellular functions where dysregulated activity is observed in various diseases. Compositions and methods use protease activity multiplexed bead-based immunoassays to profile protease activity. This platform technology integrates protease activity measurements with total protein quantification techniques. It represents a significant improvement over existing detection techniques by allowing for multiplexed, sensitive active protease measurements in complex biological samples. Exemplary multiplexed detections are realized in a single assay using a minute sample amount (e.g., 5 ?l) for active recombinant MMP-1, -2, -3, -7, 9, and 12 and those same MMPs in cell culture supernatant, menstrual fluid effluent, and peritoneal aspirates. This multiplexed platform achieves high level of sensitivities equal to or better than existing leading single-plex detection strategies.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: August 9, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Caroline Chopko Ahrens, Linda G. Griffith, Steven Robert Tannenbaum, Christi Dionne Cook, Ravindra Kodihalli, Douglas A. Lauffenburger, Evan L. Chiswick, Miles Miller
  • Patent number: 10928397
    Abstract: Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on MenaINV.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 23, 2021
    Assignees: Massachusetts Institute of Technology, Albert Einstein College of Medicine
    Inventors: Frank B. Gertler, Shannon K. Hughes, Douglas A. Lauffenburger, Jason Neil, Forest White, John S. Condeelis, Madeleine J. Oudin
  • Publication number: 20190137501
    Abstract: Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on MenaINV.
    Type: Application
    Filed: September 13, 2018
    Publication date: May 9, 2019
    Inventors: Frank B. Gertler, Shannon K. Hughes, Douglas A. Lauffenburger, Jason Neil, Forest White, John S. Condeelis, Madeleine J. Oudin
  • Publication number: 20190064167
    Abstract: Proteases regulate a wide range of normal cellular functions where dysregulated activity is observed in various diseases. Compositions and methods use protease activity multiplexed bead-based immunoassays to profile protease activity. This platform technology integrates protease activity measurements with total protein quantification techniques. It represents a significant improvement over existing detection techniques by allowing for multiplexed, sensitive active protease measurements in complex biological samples. Exemplary multiplexed detections are realized in a single assay using a minute sample amount (e.g., 5 ?l) for active recombinant MMP-1, -2, -3, -7, 9, and 12 and those same MMPs in cell culture supernatant, menstrual fluid effluent, and peritoneal aspirates. This multiplexed platform achieves high level of sensitivities equal to or better than existing leading single-plex detection strategies.
    Type: Application
    Filed: August 28, 2018
    Publication date: February 28, 2019
    Inventors: Caroline Chopko Ahrens, Linda G. Griffith, Steven Robert Tannenbaum, Christi Dionne Cook, Ravindra Kodihalli, Douglas A. Lauffenburger, Evan L. Chiswick, Miles Miller
  • Patent number: 10114023
    Abstract: Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on MenaINV.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: October 30, 2018
    Assignees: Massachusetts Institute of Technology, Albert Einstein College of Medicine, Inc.
    Inventors: Frank B. Gertler, Shannon K. Hughes-Alford, Douglas A. Lauffenburger, Jason Neil, Forest White, John S. Condeelis, Madeleine J. Oudin
  • Patent number: 10028958
    Abstract: Methods, compounds and kits relating to treating cancer, reducing kinase inhibitor or resistance, and reducing or preventing diminished ectodomain shedding are described.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: July 24, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Miles Aaron Miller, Madeleine Oudin, Aaron Samuel Meyer, Frank B. Gertler, Linda G. Griffith, Douglas A. Lauffenburger
  • Patent number: 9683231
    Abstract: The invention is directed to a method of characterizing a mechanism of action of an agent (e.g., a chemotherapeutic agent, a genotoxic agent). The method comprises contacting a plurality of populations of cells with an agent to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein said gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the agent is determined, thereby obtaining an shRNA signature of the agent, so as to identify one or more genes that mediate a response to the agent, thereby characterizing the mechanism of action of the agent. The invention is also directed an article of manufacture for characterizing a mechanism of action of a chemotherapeutic or genotoxic agent.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: June 20, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Hai Jiang, Justin Pritchard, Douglas A. Lauffenburger, Michael Hemann
  • Publication number: 20170168056
    Abstract: The present disclosure provides methods of treatment and compositions for improving and determining the efficacy of anti-cancer therapies involving tubulin remodeling or protein tyrosine kinase activity by modulating and assaying the presence of certain Mena splicing isoforms.
    Type: Application
    Filed: November 14, 2016
    Publication date: June 15, 2017
    Inventors: Frank B. Gertler, Shannon K. Hughes, Madeleine J. Oudin, Douglas A. Lauffenburger
  • Patent number: 9670486
    Abstract: In one aspect, the invention is directed to a method of characterizing a mechanism of action of a combination of agents. The method comprises contacting a plurality of populations of cells with a combination of agents to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein the gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the combination of agents is determined, thereby obtaining an shRNA signature of the combination of agents so as to identify one or more genes that mediate a response to the combination of agents, thereby characterizing the mechanism of action of the combination of agents.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: June 6, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Justin Pritchard, Douglas A. Lauffenburger, Michael Hemann
  • Publication number: 20160067250
    Abstract: Methods, compounds and kits relating to treating cancer, reducing kinase inhibitor or resistance, and reducing or preventing diminished ectodomain shedding are described.
    Type: Application
    Filed: April 17, 2015
    Publication date: March 10, 2016
    Inventors: Frank B. Gertler, Linda G. Griffith, Douglas A. Lauffenburger, Aaron Samuel Meyer, Miles Aaron Miller, Madeleine Oudin
  • Publication number: 20150044234
    Abstract: Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on MenaINV.
    Type: Application
    Filed: April 12, 2013
    Publication date: February 12, 2015
    Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventors: Frank B. Gertler, Shannon K. Hughes-Alford, Douglas A. Lauffenburger, Jason Neil, Forest White, John S. Condeelis, Madeleine J. Oudin
  • Publication number: 20140206544
    Abstract: In one aspect, the invention is directed to a method of characterizing a mechanism of action of a combination of agents. The method comprises contacting a plurality of populations of cells with a combination of agents to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein the gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the combination of agents is determined, thereby obtaining an shRNA signature of the combination of agents so as to identify one or more genes that mediate a response to the combination of agents, thereby characterizing the mechanism of action of the combination of agents.
    Type: Application
    Filed: December 16, 2011
    Publication date: July 24, 2014
    Inventors: Justin Pritchard, Douglas A. Lauffenburger, Michael Hemann
  • Publication number: 20140134635
    Abstract: The invention is directed to a method of characterizing a mechanism of action of an agent (e.g., a chemotherapeutic agent, a genotoxic agent). The method comprises contacting a plurality of populations of cells with an agent to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein said gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the agent is determined, thereby obtaining an shRNA signature of the agent, so as to identify one or more genes that mediate a response to the agent, thereby characterizing the mechanism of action of the agent. The invention is also directed an article of manufacture for characterizing a mechanism of action of a chemotherapeutic or genotoxic agent.
    Type: Application
    Filed: December 16, 2011
    Publication date: May 15, 2014
    Inventors: Hai Jiang, Justin Pritchard, Douglas A. Lauffenburger, Michael Hemann
  • Patent number: 8349311
    Abstract: The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2R?). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2? using yeast surface display to generate mutants with increased affinity for IL-2R?.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: January 8, 2013
    Assignee: Massachusetts Institute of Technology
    Inventors: Karl Dane Wittrup, Balaji M. Rao, Douglas A. Lauffenburger
  • Publication number: 20110306752
    Abstract: The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2R?). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2? using yeast surface display to generate mutants with increased affinity for IL-2R?.
    Type: Application
    Filed: April 15, 2011
    Publication date: December 15, 2011
    Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: KARL DANE WITTRUP, BALAJI M. RAO, DOUGLAS A. LAUFFENBURGER
  • Patent number: 7951360
    Abstract: The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2R?). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2? using yeast surface display to generate mutants with increased affinity for IL-2R?.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: May 31, 2011
    Assignee: Massachusetts Institute of Technology
    Inventors: K. Dane Wittrup, Balaji M. Rao, Douglas A. Lauffenburger
  • Publication number: 20100036097
    Abstract: The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2R?). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2? using yeast surface display to generate mutants with increased affinity for IL-2R?.
    Type: Application
    Filed: August 4, 2009
    Publication date: February 11, 2010
    Inventors: K. Dane Wittrup, Balaji M. Rao, Douglas A. Lauffenburger
  • Publication number: 20090311803
    Abstract: The invention discloses methods for identifying antibodies that reduce or prevent signaling by intact epidermal growth factor receptor (EGFR), or mutant EGFRs, such as EGFRvIII.
    Type: Application
    Filed: August 20, 2009
    Publication date: December 17, 2009
    Inventors: Jeffrey C. Way, Ginger Chao, Catherine Cresson, Douglas Lauffenburger, K. Dane Wittrup
  • Patent number: 7569215
    Abstract: The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2R?). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2? using yeast surface display to generate mutants with increased affinity for IL-2R?.
    Type: Grant
    Filed: July 19, 2004
    Date of Patent: August 4, 2009
    Assignee: Massachusetts Institute of Technology
    Inventors: K. Dane Wittrup, Balaji M. Rao, Douglas A. Lauffenburger
  • Publication number: 20090137784
    Abstract: Antibodies and polypeptides that bind to and/or modulate the activity of receptors in the epidermal growth factor family are provided herein.
    Type: Application
    Filed: January 13, 2009
    Publication date: May 28, 2009
    Inventors: Ginger Chao, Mark Olsen, Alejandro Wolf-Yadlin, K. Dane Wittrup, Douglas A. Lauffenburger